DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

OptiBiotix Health Plc

OTCPK:OPTB.F Stock Report

Market Cap: US$11.8m

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

OptiBiotix Health Management

Management criteria checks 3/4

OptiBiotix Health's CEO is Stephen O'Hara, appointed in Mar 2012, has a tenure of 13.83 years. total yearly compensation is £286.00K, comprised of 82.2% salary and 17.8% bonuses, including company stock and options. directly owns 10.08% of the company’s shares, worth $1.19M. The average tenure of the management team and the board of directors is 4 years and 7.8 years respectively.

Key information

Stephen O'Hara

Chief executive officer

UK£286.0k

Total compensation

CEO salary percentage82.17%
CEO tenure13.8yrs
CEO ownership10.1%
Management average tenure4yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stephen O'Hara's remuneration changed compared to OptiBiotix Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-UK£191k

Mar 31 2025n/an/a

-UK£998k

Dec 31 2024UK£286kUK£235k

-UK£2m

Sep 30 2024n/an/a

-UK£2m

Jun 30 2024n/an/a

-UK£3m

Mar 31 2024n/an/a

-UK£3m

Dec 31 2023UK£147kUK£138k

-UK£2m

Sep 30 2023n/an/a

-UK£8m

Jun 30 2023n/an/a

-UK£13m

Mar 31 2023n/an/a

-UK£5m

Dec 31 2022UK£151kUK£143k

UK£3m

Sep 30 2022n/an/a

UK£4m

Jun 30 2022n/an/a

UK£6m

Mar 31 2022n/an/a

UK£6m

Dec 31 2021UK£262kUK£254k

UK£6m

Sep 30 2021n/an/a

UK£13m

Jun 30 2021n/an/a

UK£21m

Mar 31 2021n/an/a

UK£13m

Dec 31 2020UK£229kUK£218k

UK£6m

Dec 31 2019UK£229kUK£248k

-UK£2m

Compensation vs Market: Stephen's total compensation ($USD391.27K) is below average for companies of similar size in the US market ($USD572.23K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.


CEO

Stephen O'Hara (65 yo)

13.8yrs
Tenure
UK£286,000
Compensation

Mr. Stephen Patrick O'Hara Founded OptiBiotix Health plc in March 2012 and serves as its Chief Executive. He also serves as the Board Director of ProBiotix Health Plc since April 26, 2018. Mr. O'Hara serve...


Leadership Team

NamePositionTenureCompensationOwnership
Stephen O'Hara
Founder13.8yrsUK£286.00k10.08%
$ 1.2m
Sofia Kolyda
Executive Director of Research & Development and Executive Directorno dataUK£75.00kno data
David Blain
CFO, Company Secretary & Director1.2yrsno data0.081%
$ 9.6k
Paul Cannings
Head of Operations & Quality4yrsno datano data
Kevin Newman
Corporate Development Directorno datano datano data
4.0yrs
Average Tenure
64yo
Average Age

Experienced Management: OPTB.F's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen O'Hara
Founder11.4yrsUK£286.00k10.08%
$ 1.2m
Sofia Kolyda
Executive Director of Research & Development and Executive Director7.5yrsUK£75.00kno data
David Blain
CFO, Company Secretary & Director1yrno data0.081%
$ 9.6k
Michael Christie
Senior independent director7.3yrsUK£29.00kno data
Tim Spector
Member of Scientific Advisory Group10yrsno datano data
Neil Davidson
Non-Executive Chairman8yrsUK£66.00kno data
7.8yrs
Average Tenure
65yo
Average Age

Experienced Board: OPTB.F's board of directors are considered experienced (7.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/27 12:37
End of Day Share Price 2025/10/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OptiBiotix Health Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide